Monrovia, CA, January 18, 2007 --(
PR.com)-- The Project BioShield Act was unanimously approved by the Senate, and signed by President Bush in July 2004. The measure was a response to the threat of a potential chemical, biological, radiological or nuclear (CBRN) attack on America. At an upcoming meeting in San Francisco, 4 experts will examine the performance of this program for the year and a half since it has been enacted.
Clem Lewin, Vice President of Biodefense and Policy for Acambis will moderate a sixty minute panel entitled, “The Progress of Bioshield.” He will be joined by panelists Piers Whitehead (Vice President of Corporate and Business Development for VaxGen), Beth Seidenberg (Executive in Residence at Kleiner Perkins Caufield & Byers) and Chris Colwell (Director of Vaccines Policy for BIO).
“The Progress of Bioshield” is a part of the the 4th Anti-Infectives Partnering & Deal-Making Summit taking place on January 25-26, 2007 in San Francisco, California. Other topics to be covered include the Future of Partnering in Infectious Diseases, Big Pharma Spin offs, Re-emerging Pathogens, Novel Anti-Infectives and more. For more additional details, visit www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
For more information contact Christy Bowman at GTCbio. Phone: (626) 256-6405 x101, Fax: (626) 256-6460, Email: Christy.bowman@gtcbio.com
###
